by Rod Raynovich | Aug 12, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Microfluidics released earnings on Tuesday with good results: $4.5M in Q2 Revenue a 30% increase over the same quarter in 2009. Net Income of $143k compared to a loss of $177k in the same quarter of 2009.($396k before EBITA). Achieved a gross margin of 64%. Began...
by Rod Raynovich | Aug 11, 2010 | BIOgraph, Macro
Be thankful for the July rally that brought you 8-10% gains.It is time to protect your portfolio and play defense as market seasonality favors the bears from mid-August through mid-October. September can be the worse month so be patient for the year-end rally.To make...
by Rod Raynovich | Aug 10, 2010 | BIOgraph
The market recovered from bigger losses with the S&P down 0.7%. The FED said economic growth will be modest and made two decisions for a neutral policy : taking money from mortgage securities to buy treasuries and keeping its balance sheet unchanged. This means...
by Rod Raynovich | Aug 3, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Q1 P Original Price % Return Q 2 P 8/2/10 % Recom 3/29/10 P Ret. Abaxis ABAX 26.8 2/2/09 15 79 21.2 20.7 30 Celera CRA 6.8 3/28/10 7 6.49 6.85 -2 Exact Sci EXAS UR 4.2 Genomic Health GHDX UR 12.6 13.1 Genoptix GXDX UR 17.2 18.13 GenProbe GPRO 48 2/2/09 45 7 46.3 45.9...
by Rod Raynovich | Aug 3, 2010 | BIOgraph
Last week’s Plenary Session from the AACC featured Paul Ridker.MD,MPH from Brigham and Women’s Hospital ,Boston,MA speaking about Inflammation,hsCRP and Cardiovascular Prevention. The session reviewed data from the JUPITER trial for the use of statins in...
by Rod Raynovich | Aug 2, 2010 | BIOgraph
The Wall Street Journal reported on Friday that Novartis (NVS) will collaborate with Pathwork Diagnostics on the development of biomarkers across a range of cancer types that would capitalize on the trend to “match patients with the right medicines”....
by Rod Raynovich | Jul 30, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The intersection of good earnings and a strong AACC showing boosted Diagnostic stocks this week with the following big movers today on earnings reports: Abaxis (ABAX) $20.81 up $13.7%,GenProbe (GPRO) $45.85 up 8.14%,Neogen (NEOG) $29.85 up 3.4% and Quidel (QDEL)...
by Rod Raynovich | Jul 29, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Here are some brief notes from our visit to the AACC in Anaheim and recent earnings reports. Rayno Diagnostic and Tools Portfolio Abaxis (ABAX)-under review- and Quidel (QDEL) report today.We added Quidel to our model portfolio on 6/16 at $12.40.The stock is trading...
by Rod Raynovich | Jul 26, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors . A stock rally in the sector was ignited last week by earnings announcements from four major mid-cap...
by Rod Raynovich | Jul 23, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Good financials have perked up interest is mid-cap Diagnostics companies that released results today. Immucor (BLUD) a global leader in automated analysis of blood transfusion systems had revenue of $82.9M up 5% from prior year quarter with diluted earnings of $0.30...
